Bioperfectus SSNP-2000B Nucleic Acid Extraction System Wins iF Design Award 2022

Company news
2022-04-12

 

Shanghai, China, April 12, 2022—Today, Jiangsu Bioperfectus Technologies Co., Ltd. (Bioperfectus) is pleased to announce that our SSNP-2000B Nucleic Acid Extraction System has won the iF DESIGN AWARD 2022 in recognition of its unique structure and innovative design.

 

iF DESIGN AWARD is one of the most prestigious design awards worldwide. Each iF Design Award Final Jury entry is assessed by several jurors in five aspects criteria, including Idea, Form, Function, Differentiation, and Impact. Bioperfectus SSNP-2000B Nucleic Acid Extraction System stands out among over 11,000 entries from 57 countries with its simple, minimalist, unique, and eco-friendly design concept, which combines multi-function in its high-quality product specifications.

 

SSNP-2000B is an industry innovative automatic nucleic acid extractor that is compact and lightweight and perfectly fits the biosafety cabinet. It adopts the magnetic bead method to extract and purify nucleic acid from various clinical standard samples. A built-in HEPA filter, which can create an air circulation inside combined with a UV lamp, can dramatically avoid contamination among samples and keep the accuracy of results. In addition, the extraction process for COVID-19, HPV, STD, and vector-borne samples do not require additional reagents, and the fully automated operation reduces labor costs. It can maximize the efficiency of the assay.

 

“It is an honor to earn iF design recognition upon the celebration of Bioperfectus 12th Anniversary,” said Deputy General Manager of Bioperfectus International Sales & Marketing Division, “Our highly talented and experienced engineering and R&D teams, focused on listening carefully to laboratory technicians and healthcare workers throughout the entire research and development process. They responded to those needs in designing each aspect of the Bioperfectus System. We’re excited to be bringing this new option to our partners and end-users.”

 

Looking ahead, Bioperfectus will continue its commitment to offering high-quality molecular diagnostic laboratory solutions and services to our customers around the globe.

 

About Bioperfectus
Bioperfectus, a public listed company on Shanghai Stock Exchange (SSE:688399), has been one of the leading molecular diagnostic solution providers specializing in infectious diseases ever since 2010. With headquarters located in Jiangsu, subsidiaries in Shanghai, Beijing, Xi'an, Taizhou, Hainan, and Yinchuan. Bioperfectus is pioneering in the molecular diagnostics market with our products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automation laboratory devices. Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream to create a healthier future for our next generations. For more information, please click here.

About the iF Design Award
Since 1954, the iF DESIGN AWARD has been recognized as an arbiter of quality for excellent design. The iF Design brand is renowned worldwide for outstanding design services, and the iF DESIGN AWARD is one of the most important design prizes in the world. It honors design achievements in all disciplines: product, packaging, communication and service design, architecture and interior architecture as well as professional concept, user experience (UX), and user interface (UI). All award-winning entries are featured on www.ifdesign.com and published in the iF Design App.  For more information, please click here.

MOST READ

Your Problem, Our Solution

At Bioperfectus, the excellent experience of our customers is our goal and the key to our job. Last Wednesday, we completed online technical training for our distribution local support in the Asia Pacific region. The webinar covers insightful training on Bioperfectus Nucleic Acid Extraction System, Nucleic Acid Extraction Kit, Real-Time PCR System, and product demonstration on the newly launched SAW-96 Nucleic Acid Extraction Workstation.

2022-08-16

MHRA Registration Approval for BioPerfectus Monkeypox Virus Real Time PCR Kit

Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “BioPerfectus”) is pleased to announce that Monkeypox Virus Real Time PCR Kit has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and is now officially available for Great Britain and Northern Ireland market.

2022-08-11

A Simplified HPV-DNA Workflow for Better Preventing Cervical Cancer

With over 600 thousand new cases and more than half that would lead to death each year, cervical cancer is listed as the fourth most frequent cancer among women worldwide.

2022-08-05